Last reviewed · How we verify
Arbaclofen Placarbil MR Prototype B — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Arbaclofen Placarbil MR Prototype B (Arbaclofen Placarbil MR Prototype B) — Indivior Inc.. Arbaclofen placarbil is a prodrug that is converted to arbaclofen, a GABA-B receptor agonist that modulates neurotransmission in the central nervous system.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Arbaclofen Placarbil MR Prototype B TARGET | Arbaclofen Placarbil MR Prototype B | Indivior Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Arbaclofen Placarbil MR Prototype B CI watch — RSS
- Arbaclofen Placarbil MR Prototype B CI watch — Atom
- Arbaclofen Placarbil MR Prototype B CI watch — JSON
- Arbaclofen Placarbil MR Prototype B alone — RSS
Cite this brief
Drug Landscape (2026). Arbaclofen Placarbil MR Prototype B — Competitive Intelligence Brief. https://druglandscape.com/ci/arbaclofen-placarbil-mr-prototype-b. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing